NASDAQ:INMB

INmune Bio (INMB) Stock Price, News & Analysis

INmune Bio logo
$0.83 -0.07 (-7.50%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.85 +0.02 (+2.30%)
As of 11/20/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About INmune Bio Stock (NASDAQ:INMB)

Advanced

Key Stats

Today's Range
$0.82
▼
$0.92
50-Day Range
$0.83
▼
$2.33
52-Week Range
$0.82
▼
$2.60
Volume
326,631 shs
Average Volume
308,360 shs
Market Capitalization
$25.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50
Consensus Rating
Moderate Buy

Company Overview

INmune Bio, Inc. is a clinical-stage biotechnology company developing treatments that target the innate immune system. The company’s research focuses on using immune responses to address cancer and inflammatory conditions, including neuroinflammation.

Its pipeline includes XPro1595, a selective inhibitor of soluble tumor necrosis factor being studied for conditions including Alzheimer’s disease, and INKmune, an investigational cell therapy designed to enhance natural killer cell activity against cancer. These therapies remain under clinical development.

INmune Bio is headquartered in La Jolla, California. The company is led by Raymond J. Tesi, M.D., its co-founder, president and chief executive officer.

AI Generated. May Contain Errors.

INmune Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

INMB MarketRank™: 
1.70669072737 of 5 stars

INmune Bio scored higher than 34% of companies evaluated by MarketBeat, and ranked 685th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    INmune Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    INmune Bio has a consensus price target of $2.50, representing about 202.3% upside from its current price of $0.83.

  • Amount of Analyst Coverage

    INmune Bio has only been the subject of 2 research reports in the past 90 days.

  • Read more about INmune Bio's stock forecast and price target.
  • Price to Book Value per Share Ratio

    INmune Bio has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.93% of the float of INmune Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    INmune Bio has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in INmune Bio has recently decreased by 7.89%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    INmune Bio does not currently pay a dividend.

  • Dividend Growth

    INmune Bio does not have a long track record of dividend growth.

  • News Sentiment

    INmune Bio has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • Search Interest

    2 people have searched for INMB on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, INmune Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.40% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    12.72% of the stock of INmune Bio is held by institutions.

  • Read more about INmune Bio's insider trading history.
Receive INMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INMB Stock News Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More Headlines

INMB Stock Analysis - Frequently Asked Questions

INmune Bio's stock was trading at $1.56 at the beginning of 2026. Since then, INMB shares have decreased by 47.0% and is now trading at $0.8270.

INmune Bio, Inc. (NASDAQ:INMB) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.02.
Read the conference call transcript
.

INmune Bio (INMB) raised $20 million in an initial public offering (IPO) on the week of February 4th 2019. The company issued 2,500,000 shares at $8.00 per share.

Top institutional investors of INmune Bio include Goldman Sachs Group Inc. (0.52%), State Street Corp (0.42%), Marshall Wace LLP (0.29%) and Russell Investments Group Ltd. (0.09%). Insiders that own company stock include Raymond Joseph Tesi, David J Moss and Scott Juda.
View institutional ownership trends
.

Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that INmune Bio investors own include Cassava Sciences (FLNA), NVIDIA (NVDA), Palantir Technologies (PLTR), Plug Power (PLUG), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
11/05/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INMB
CIK
1711754
Fax
N/A
Employees
21
Year Founded
N/A

Price Target and Rating

High Price Target
$2.50
Low Price Target
$2.50
Potential Upside/Downside
+202.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.60)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$45.93 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-81.71%
Return on Assets
-62.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.41
Quick Ratio
6.41

Sales & Book Value

Annual Sales
$50 thousand
Price / Sales
512.08
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.58 per share
Price / Book
1.43

Miscellaneous

Outstanding Shares
30,960,000
Free Float
24,334,000
Market Cap
$25.60 million
Optionable
Optionable
Beta
0.97
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:INMB) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners